Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer

Cancer Letters

Volumn 348, Issue 1-2, 2014, Pages 20-28

  Chen, Shaohua ^a   Wang, Guan ^a   Niu, Xiaojia ^a   Zhao, Jianyun ^a   Tan, Wenxi ^a   Wang, Hebin ^a   Zhao, Lijing ^a   Ge, Yubin ^a,b  

^a JILIN UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug combination; Obatoclax; Olaparib; Pancreatic cancer

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OBATOCLAX; OLAPARIB; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; DRUG POTENTIATION; GROWTH DISORDER; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

DRUG COMBINATION; OBATOCLAX; OLAPARIB; PANCREATIC CANCER;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NECROSIS; PANCREATIC NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900503589     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.010     Document Type: Article

References (47)

1. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
2. Bolderson E., Richard D.J., Zhou B.B., Khanna K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15:6314-6320.
3. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 1997, 15:2403-2413.
4. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
5. Dumay A., Laulier C., Bertrand P., Saintigny Y., Lebrun F., Vayssiere J.L., Lopez B.S. Bax and Bid, two proapoptotic Bcl-2 family members, inhibit homologous recombination, independently of apoptosis regulation. Oncogene 2006, 25:3196-3205.
6. Edwards H., Xie C., LaFiura K.M., Dombkowski A.A., Buck S.A., Boerner J.L., Taub J.W., Matherly L.H., Ge Y. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009, 114:2744-2752.
7. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
8. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., Teague J.W., Campbell P.J., Stratton M.R., Futreal P.A. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39:D945-950.
9. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discovery 2010, 9:447-464.
10. Giovannetti E., Mey V., Nannizzi S., Pasqualetti G., Del Tacca M., Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther. 2006, 5:1387-1395.
11. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
12. Huang S., Okumura K., Sinicrope F.A. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15:150-159.
13. Hwang J.J., Kuruvilla J., Mendelson D., Pishvaian M.J., Deeken J.F., Siu L.L., Berger M.S., Viallet J., Marshall J.L. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:4038-4045.
14. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
15. Karl E., Zhang Z., Dong Z., Neiva K.G., Soengas M.S., Koch A.E., Polverini P.J., Nunez G., Nor J.E. Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ. 2007, 14:1657-1666.
16. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., Bornmann W., Kantarjian H., Viallet J., Samudio I., Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008, 68:3413-3420.
17. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell 2010, 39:8-24.
18. Kullmann F., Hollerbach S., Dollinger M.M., Harder J., Fuchs M., Messmann H., Trojan J., Gabele E., Hinke A., Hollerbach C., Endlicher E. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br. J. Cancer 2009, 100:1032-1036.
19. Laulier C., Barascu A., Guirouilh-Barbat J., Pennarun G., Le Chalony C., Chevalier F., Palierne G., Bertrand P., Verbavatz J.M., Lopez B.S. Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes. Cancer Res. 2011, 71:3590-3602.
20. Leber B., Geng F., Kale J., Andrews D.W. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev. Mol. Med. 2010, 12:e28.
21. Li J., Saif M.W. Advancements in the management of pancreatic cancer. JOP: J. Pancreas 2009, 10:109-117.
22. Liang J.T., Huang K.C., Jeng Y.M., Lee P.H., Lai H.S., Hsu H.C. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br. J. surgery 2004, 91:355-361.
23. Maisey N.R., Norman A.R., Hill A., Massey A., Oates J., Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br. J. Cancer 2005, 93:740-743.
24. McCabe N., Turner N.C., Lord C.J., Kluzek K., Bialkowska A., Swift S., Giavara S., O'Connor M.J., Tutt A.N., Zdzienicka M.Z., Smith G.C., Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006, 66:8109-8115.
25. Michl P., Gress T.M. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013, 62:317-326.
26. Miyamoto Y., Hosotani R., Wada M., Lee J.U., Koshiba T., Fujimoto K., Tsuji S., Nakajima S., Doi R., Kato M., Shimada Y., Imamura M. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 1999, 56:73-82.
27. Nakai Y., Kawabe T., Isayama H., Sasaki T., Yagioka H., Yashima Y., Kogure H., Arizumi T., Togawa O., Ito Y., Matsubara S., Hirano K., Sasahira N., Tsujino T., Tada M., Omata M. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology 2008, 75:120-126.
28. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., Goulet D., Viallet J., Belec L., Billot X., Acoca S., Purisima E., Wiegmans A., Cluse L., Johnstone R.W., Beauparlant P., Shore G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 2007, 104:19512-19517.
29. Park J.K., Paik W.H., Ryu J.K., Kim Y.T., Kim Y.J., Kim J., Song B.J., Park J.M., Yoon Y.B. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1446 patients from the pancreatic cancer cohort in a single institution. PLoS ONE 2013, 8:e78977.
30. Penchev V.R., Rasheed Z.A., Maitra A., Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2012, 18:4277-4284.
31. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:4527-4531.
32. Porcelli L., Quatrale A.E., Mantuano P., Leo M.G., Silvestris N., Rolland J.F., Carioggia E., Lioce M., Paradiso A., Azzariti A. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol. Oncol. 2013, 7:308-322.
33. Rahmani M., Aust M.M., Attkisson E., Williams D.C., Ferreira-Gonzalez A., Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012, 119:6089-6098.
34. Rajesh M., Mukhopadhyay P., Batkai S., Godlewski G., Hasko G., Liaudet L., Pacher P. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem. Biophys. Res. Commun. 2006, 350:352-357.
35. Rajesh M., Mukhopadhyay P., Godlewski G., Batkai S., Hasko G., Liaudet L., Pacher P. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem. Biophys. Res. Commun. 2006, 350:1056-1062.
36. Reed E. DNA damage and repair in translational oncology: an overview. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:4511-4516.
37. Rossetto D., Truman A.W., Kron S.J., Cote J. Epigenetic modifications in double-strand break DNA damage signaling and repair. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:4543-4552.
38. Saintigny Y., Dumay A., Lambert S., Lopez B.S. A novel role for the Bcl-2 protein family: specific suppression of the RAD51 recombination pathway. EMBO J. 2001, 20:2596-2607.
39. Strimpakos A., Saif M.W., Syrigos K.N. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev. 2008, 27:495-522.
40. Sultana R., McNeill D.R., Abbotts R., Mohammed M.Z., Zdzienicka M.Z., Qutob H., Seedhouse C., Laughton C.A., Fischer P.M., Patel P.M., Wilson D.M., Madhusudan S. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int. J. Cancer 2012, 131:2433-2444.
41. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., Friedlander M., Arun B., Loman N., Schmutzler R.K., Wardley A., Mitchell G., Earl H., Wickens M., Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
42. Valerie K., Povirk L.F. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003, 22:5792-5812.
43. Wang G., He J., Zhao J., Yun W., Xie C., Taub J.W., Azmi A., Mohammad R.M., Dong Y., Kong W., Guo Y., Ge Y. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS ONE 2012, 7:e52095.
44. Wang Q., Gao F., May W.S., Zhang Y., Flagg T., Deng X. Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol. Cell 2008, 29:488-498.
45. Xie C., Edwards H., Xu X., Zhou H., Buck S.A., Stout M.L., Yu Q., Rubnitz J.E., Matherly L.H., Taub J.W., Ge Y. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:5499-5510.
46. Xu X., Xie C., Edwards H., Zhou H., Buck S.A., Ge Y. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS ONE 2011, 6:e17138.
47. Ziske C., Schlie C., Gorschluter M., Glasmacher A., Mey U., Strehl J., Sauerbruch T., Schmidt-Wolf I.G. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br. J. Cancer 2003, 89:1413-1417.